EyeControl, is a privately-held growing startup, established in 2016 by individuals, who share unique personal connections to Locked-in patients. We are pioneers of medical technology, specializing in innovative solutions that address acute care communication and Delirium management, unmet healthcare needs estimated at over $100B in US annual costs.
EyeControl implements disruptive AI technologies that connect people and bridge information barriers, facilitating better medical care and decision-making. Our eye-tracking wearable and innovative platform empower comprehensive, round-the-clock, bi-directional connectivity between patients with communication difficulties, their families, and medical teams.
The company’s value-based care approach of personalized communication is intended to mitigate Delirium, diminish healthcare costs, and shorten the length of hospital stay.
Recognized for its cutting-edge medical innovation, the company is supported by the European Innovation Council, Israel Innovation Authority, investors and advisors representing various sectors.
EyeControl’s devices are FDA listed and CE marked as communication solutions; our outpatient product, EyeControl-Home, is government reimbursed in Israel, the UK, and the US. EyeControl-Med, our healthcare facility product, is undergoing clinical trials at US and Israeli hospitals, validating its efficacy in being the first technology platform mitigating Delirium via communication.